Evidence map›Paper›PMID 24830425›Full record

ArticlePloS one2014

Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients.

Melanie Werner-Klein, Judith Proske, Christian Werno, Katharina Schneider, Hans-Stefan Hofmann, Brigitte Rack, Stefan Buchholz, Roman Ganzer, Andreas Blana, Birgit Seelbach-Göbel and 3 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Transgenic Mouse Models in Cancer Research.Frontiers in oncology · 2018
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Melanie Werner-KleinInstitute of Immunology, University of Regensburg, Regensburg, Germany.
Judith ProskeInstitute of Immunology, University of Regensburg, Regensburg, Germany.
Christian WernoProject Group Personalized Tumor Therapy, Fraunhofer Institute of Toxicology and Experimental Medicine, Regensburg, Germany.
Katharina SchneiderExperimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Hans-Stefan HofmannDepartment of Thoracic Surgery, University Regensburg, Regensburg, Germany.
Brigitte RackDepartment of Gynecology and Obstetrics, Ludwig-Maximilians-Universität München, Munich, Germany.
Stefan BuchholzDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.
Roman GanzerDepartment of Urology, University of Leipzig, Leipzig, Germany.
Andreas BlanaDepartment of Urology, Fuerth Hospital, Fuerth, Germany.
Birgit Seelbach-GöbelClinic of Gynecology and Obstetrics St. Hedwig, University of Regensburg, Regensburg, Germany.
Ulrich NitscheDepartment of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Daniela N MännelInstitute of Immunology, University of Regensburg, Regensburg, Germany.
Christoph A KleinProject Group Personalized Tumor Therapy, Fraunhofer Institute of Toxicology and Experimental Medicine, Regensburg, Germany; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor xenografts in immunodeficient mice, while routinely used in cancer research, preclude studying interactions of immune and cancer cells or, if humanized by allogeneic immune cells, are of limited use for tumor-immunological questions. Here, we explore a novel way to generate cancer models with an autologous humanized immune system. We demonstrate that hematopoietic stem and progenitor cells (HSPCs) from bone marrow aspirates of non-metastasized carcinoma patients, which are taken at specialized centers for diagnostic purposes, can be used to generate a human immune system in NOD-scid IL2rγ(null) (NSG) and HLA-I expressing NSG mice (NSG-HLA-A2/HHD) comprising both, lymphoid and myeloid cell lineages. Using NSG-HLA-A2/HHD mice, we show that responsive and self-tolerant human T cells develop and human antigen presenting cells can activate human T cells. As critical factors we identified the low potential of bone marrow HSPCs to engraft, generally low HSPC numbers in patient-derived bone marrow samples, cryopreservation and routes of cell administration. We provide here an optimized protocol that uses a minimum number of HSPCs, preselects high-quality bone marrow samples defined by the number of initially isolated leukocytes and intra-femoral or intra-venous injection. In conclusion, the use of diagnostic bone marrow aspirates from non-metastasized carcinoma patients for the immunological humanization of immunodeficient mice is feasible and opens the chance for individualized analyses of anti-tumoral T cell responses.

Indexed as

Hematopoietic Stem Cell TransplantationAnimalsAntigens, CD34Bone MarrowBreast NeoplasmsDisease Models, AnimalEsophageal NeoplasmsFemaleHematopoietic Stem CellsHumansLung NeoplasmsMaleMice, Inbred C57BLMice, Inbred NODMice, SCIDProstatic NeoplasmsAntigens, CD34

Identifiers

PMID24830425
PMCPMC4022674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.